3 Companies That Need to Kick Their CEO to the Curb


All three companies are struggling to overcome obstacles that may be holding down their stock price, and it may take A highly contentious showdown for the control of Immunomedics suggests that it may be time for founder and board member David Goldenberg and his wife, CEO Cynthia Sullivan, to head for the exit. Immunomedics inked a deal to license commercial rights to its lead product candidate, IMMU-132, last month, but the deal drew the ire of venBio, an activist hedge fund that's been advocating for significant change in the C-suite, and that owns about 10% of the company.



from Biotech News